A clinical trial has commenced to test the effectiveness of a low-dose regimen of the anti-malarial drug Chloroquine to prevent coronavirus illness.
The clinical trial is being funded by Defence and managed by the national Medical Countermeasures Initiative led by DMTC Limited. Experts with experience in clinical trials from DMTC are working alongside personnel at the trial site, the ADF Malaria and Infectious Diseases Institute.
The trial will focus on military healthcare and civilian healthcare workers at the frontline of the national response to COVID-19.
Chloroquine is a well-known drug that is already used around the world for the prevention and treatment of malaria as well as the treatment of some inflammatory and connective tissue diseases.
DMTC CEO Dr Mark Hodge urged caution in the race to provide answers to combating COVID-19.
“Clinical trials are essential to establish global benchmarks and ultimately to prove whether this drug, at these prescribed dose amounts, can prevent infection,” Dr Hodge said.
“Novel medications can take a long time to get through all the tests and approvals that are needed to confirm safety, quality and effectiveness. Re-purposing of an existing drug with a known safety profile has potential benefits in regard to expediting conclusive results.”
Because its safety profile is well understood, the trial can be undertaken rapidly to the high standards required by Australian and international pharmaceutical regulators. (more…)
DMTC’s Awards for Excellence provided an opportunity to acknowledge two members of the DMTC community for their long-standing commitment to collaboration and industrially-relevant research. (more…)
Capability Improvement Award – Winner: Sustainment of Emergent Materials team
This collaborative team (working under the auspices of DMTC Project Team 5.77) has worked extensively on the development of laser additive deposition (LAD) technology for the past 10 years and has achieved significant outcomes for commercial and Defence customers.
Smiles all-round for members of the team awarded the DMTC Capability Improvement Award for 2020
For defence customers, innovative approaches to, and adoption of new technologies for, sustainment of fleets is crucial, especially in light of the cost pressures associated with life cycle support on military platforms. Through this project and previous enabling research, DMTC has been an integral partner in helping to generate a sovereign industrial capability in Australia in laser repair technology. RUAG Australia has shown repeatedly that repairing components, rather than replacing them, enables Defence to achieve the desired structural performance rates and fleet availability results at a fraction of the cost, and in fractions of the time.
“RUAG Australia continues to be a top performer in innovation in Australia. Working together with DMTC has directly proven that this passionate pursuit of innovation and collaborative research and development ensures solid benefits for all stakeholders,” Neil Matthews, Chief Technical Advisor & Senior Manager Additive Technologies, RUAG Australia said.
This project has not only demonstrated the successful geometrical restoration of actual aircraft components, but also the viability of LAD technology for repair of Defence-grade materials. Researchers from RUAG, Swinburne and RMIT developed and supported the establishment of state-of-the-art sustainment and repair laser cladding facility at RUAG which is now fully operational through the funding of the Defence Capability and Technology Demonstrator (CTD) Program. The work carried out by research partners, RMIT and Swinburne, ensured that the restored Defence components meet certification, operational and design requirements.
Collaboration Award – Winner: Dr Mitali Sarkar-Tyson
Dr Mitali Sarkar-Tyson from the School of Biomedical Sciences at The University of Western Australia received the coveted Collaboration Award at the 2020 DMTC Annual Conference.
Dr Sarkar-Tyson with CEO DMTC, Dr Mark Hodge, and special guest dinner speaker Adam Goodes (right)
Dr Sarkar-Tyson has shown an incredible work ethic and commitment to developing our sovereign industrial capability in the medical countermeasures domain over the last several years.
She is currently leading a DMTC project out of The University of Western Australia in collaboration with DST Group, the Peter Doherty Institute, the University of Wurzburg, the University of Exeter, DSTL and now Monash University. This project is developing novel anti-virulence compounds against a range of bio-warfare pathogens. In addition to the highly significant research she has conducted for this project, she has also contributed to 72 scientific research publications across the fields of antimicrobial resistance and molecular biology.
The DMTC Collaboration Award recognises an individual who embodies the spirit of collaboration, and Dr Sarkar-Tyson has truly embodied collaboration through bringing together a network of international researchers and coordinating a multi-disciplinary team that can respond to bio-threat pathogens and the growing threat of antimicrobial resistance.
